Teacher: In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
Teacher: Now, understand the problem? If you are still confused, see the following example:
SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Solution: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Reason: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

Now, solve this instance: SECTION 1. SHORT TITLE; FINDINGS.

(a) Short Title.--This act may be cited as the Cooperative Units of
Research in Infectious Disease (CURID) of 1994.
(b) Findings.--Congress finds that--
(1) despite the development of modern technology for water
purification, food preparation, sterilization and disinfection
coupled with the discovery of antibiotics and a limited number
of highly effective vaccines, the advent of AIDS, the re-
emergence of tuberculosis, the emergence of newly infectious
agents and a significant increase in food and water borne
diseases in recent years pose new threats to the health and
well-being of all citizens;
(2) the era of molecular biology and intensive research
efforts in AIDS have produced powerful technology for the rapid
and sensitive detection of new infectious agents which have
resulted in the development of new concepts of infectious
diseases;
(3) advances in the scientific understanding of the
functions of the human body's defense mechanisms and the
critical roles of both the patient and the infecting agent's
genetic characteristics are rapidly leading to the belief that
a number of chronic diseases of humans presently of unknown
etiology may be caused by infectious agents;
(4) chronic illnesses like lung, arthritis and related
diseases are increasing at alarming rates and, according to
1994 National Centers for Disease Control and Prevention data,
the incidence of arthritis alone is estimated to increase by 57
percent and affect 54.9 million people in the United States by
the year 2020;
(5) the economic losses associated with these disabling
diseases will continue to cost our society billions of dollars
annually if the Federal Government does not invest in essential
research initiatives designed to build upon our ability to
detect new infectious agents and fully investigate new concepts
of the etiology of chronic diseases;
(6) determining and demonstrating causality of diseases
like chronic lung disease, rheumatoid arthritis and rheumatic
diseases by an infectious agent could lead to early and
accurate diagnosis and treatment of the disease which would
dramatically reduce medical costs and morbidity and mortality;
and
(7) addressing the potential role of infectious agents in
chronic diseases necessitates a different research approach
than currently exists and sustained funding of collaborative
research groups.

SEC. 2. SPECIFIC PROVISIONS; ESTABLISHMENT OF COOPERATIVE UNITS OF
RESEARCH IN INFECTIOUS DISEASES.

(a) In General.--Infectious Disease Research and Clinical Units of
Excellence will be established jointly by the National Institute of
Allergy and Infectious Diseases of the National Institutes of Health
and the National Center for Infectious Diseases of the National Centers
for Disease Control and Prevention.
(b) Purpose.--These cooperative units will be dedicated to finding
the cause, prevention and cure of chronic inflammatory diseases of
suspected infectious etiology and committed to giving priority to
diseases like arthritis and chronic lung disease which hold the most
promise for beneficial research results.
(c) Establishment of Units.--The establishment of the Infectious
Disease Research and Clinical Units of Excellence shall be based upon
past research performance of researchers working on specific
microorganisms.
(1) The units will be responsible for--
(A) evaluation of patient specimens for the
presence of infectious agents;
(B) characterization of the immune response to
these infectious agents; and
(C) characterization of the genetic background of
patients.
(2) Personnel to staff these units will be selected based
upon the proven track record of individuals who--
(A) have demonstrated the capability of using
molecular diagnostic techniques for detection of
fastitious infectious agents; and
(B) possess proven clinical experience.
(3) The units will provide laboratory support for a network
of Clinical Units for patient enrollment and patient
management.
(4) National Center for Infectious Diseases of the National
Centers for Disease Control and Prevention will provide the
epidemiological and investigative skills for a network of
Clinical Units.
(5) The initial period of grant funding for the units will
be up to ten but no less than five years.
(d) Coordination of Research Program and Development of Strategic
Research Plan.--The National Institute of Allergy and Infectious
Diseases shall be the lead agency.
(1) The Director of the National Institute of Allergy and
Infectious Diseases shall be responsible for the establishment
of no more than 10 research and clinical units at any given
time.
(2) The designation of research and clinical units shall be
carried out in consultation with the Director of the National
Center for Infectious Diseases as well as expert extramural
scientists.
(3) The directors of the research and clinical units will
be responsible for the development of the research plan.

SEC. 3. AUTHORIZATION OF APPROPRIATIONS.

There are authorized to be appropriated $25,000,000 for each of the
fiscal years 1996 through 2006. At the end of this 10 year period, the
effectiveness of this research approach will be evaluated and the need
for future funding, if any, will be determined by the National Advisory
Councils of the National Institute of Allergy and Infectious Diseases
and the National Center for Infectious Diseases. The National Advisory
Councils shall submit a report of its findings and recommendations to
the appropriate authorizing committees of the House and the Senate.
Student:
Cooperative Units of Research in Infectious Disease (CURID) Act of 1994 - Requires Infectious Disease Research and Clinical Units of Excellence to be established jointly by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health and the National Center for Infectious Diseases of the National Centers for Disease Control and Prevention. Provides that the Units will be dedicated to finding the cause, prevention, and cure of chronic inflammatory diseases of suspected infectious etiology and committed to giving priority to diseases like arthritis and chronic lung disease which hold the most promise for beneficial research results.
Requires the establishment of the Units to be based upon past research performance of researchers working on specific microorganisms. Makes the Units responsible for: (1) evaluation of patient specimens for the presence of infectious agents; (2) characterization of the immune response to these infectious agents; and (3) characterization of the genetic background of patients.
Sets forth provisions regarding personnel, laboratory support, networking, and the initial period of grant funding.
Makes NIAID the lead agency. Apportions responsibility for various aspects of the research program and development of a strategic research plan.
Authorizes appropriations.